跳转至内容
Merck

V3501

Sigma-Aldrich

维生素 K 1

viscous liquid

别名:

2-甲基-3-植基-1,4-萘醌, 叶绿醌, 植物甲萘醌, 维生素 K1(20)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C31H46O2
CAS号:
分子量:
450.70
Beilstein:
2568816
EC號碼:
MDL號碼:
分類程式碼代碼:
12352205
eCl@ss:
34058015
PubChem物質ID:
NACRES:
NA.28

生物源

synthetic (organic
inorganic)

形狀

viscous liquid

顏色

yellow to orange

折射率

n20/D 1.527 (lit.)

mp

−20 °C (lit.)

密度

0.984 g/mL at 25 °C (lit.)

儲存溫度

2-8°C

SMILES 字串

O=C(C1=CC=CC=C21)C(C)=C(C/C=C(CCC[C@@H](CCC[C@H](C)CCCC(C)C)C)\C)C2=O

InChI

1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1

InChI 密鑰

MBWXNTAXLNYFJB-NKFFZRIASA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

维生素K1/叶绿醌是异戊烯化的萘醌。由植物、绿藻和某些种类的蓝细菌产生。

應用

维生素K1 用于制备培养基。

生化/生理作用

维生素K1(叶绿醌)是脂溶性多环芳香酮,用作辅因子,形成凝血因子II(凝血酶原)、VII、IX和X以及抗凝血因子蛋白C和抗凝血因子蛋白S,也可用作细胞信号传导因子。维生素K1对凝血、骨骼和血管代谢至关重要。人类膳食中维生素K 最重要的来源是绿叶蔬菜和植物油中所含的叶绿醌。

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Phylloquinone (vitamin K1): occurrence, biosynthesis and functions
Basset J G, et al.
Mini-Reviews in Medicinal Chemistry (2017)
Bacteroides disiens sp. nov. and Bacteroides bivius sp. nov. from human clinical infections
Holdeman L V and Johnson J L
International Journal of Systematic and Evolutionary Microbiology (1977)
Beverly Murray et al.
The Journal of antimicrobial chemotherapy, 75(8), 2149-2155 (2020-04-15)
Ibezapolstat (ACX-362E) is the first DNA polymerase IIIC inhibitor undergoing clinical development for the oral treatment of Clostridioides difficile infection (CDI). In this study, the in vitro activity of ibezapolstat was evaluated against a panel of 104 isolates of C.
Ellen M Apalset et al.
Bone, 49(5), 990-995 (2011-08-16)
Evidence of the effect of vitamin K on bone health is conflicting. The aim was to investigate the association between intake of vitamins K1 and K2 and subsequent risk of hip fracture in a general population sample, as well as
Edward P A Gebuis et al.
Haematologica, 96(4), 583-589 (2011-01-05)
Poor anticoagulant stability in patients using vitamin K antagonists is a risk factor for both bleeding and thrombosis. In previous studies supplementation with low dose vitamin K(1) was shown to improve the stability of anticoagulant control. We set up a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门